Previous 10 | Next 10 |
Capital Structure Idea Slides Chart GBT's 50MA has served as key support throughout 2019 and the recent dip appears to allow investors another advantageous buying point. Introduction Global Blood Therapeutics ( GBT ) remains a top conviction pick in 2Q 2019, as the compa...
Global Blood Therapeutics (NASDAQ: GBT ): Q1 GAAP EPS of -$0.87 beats by $0.06. More news on: Global Blood Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
SOUTH SAN FRANCISCO, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today reported recent business progress and financial results for the first quarter ended March 31, 2019. “With a goal of getting voxelotor to the sickle cel...
Source: Shutterstock The stock market has continued to edge higher and the two major indexes, the Nasdaq ( QQQ ) and S&P 500 ( SPY ), touched the all-time high milestone last week. The steady gain reflects a diminishing concern relating to the pace of a global economic slowdown, as m...
By Jonathan Liss Listen and subscribe to the Marketplace Roundtable on these podcast platforms: iTunes/Apple Podcasts Spotify Stitcher Jonathan Faison doesn't want prospective biotech investors to think that they need some sort of "special sauce" to succeed...
From the Big Picture to Individual Stock Breakouts Last year I highlighted the Healthcare Biotech Sector Breakout and correctly forecasted "at least 20% gains in sector ETFs and even higher for many key biotech stocks in the near term." I believe the technical analysis that I will det...
Never lose money. Stay rational and stick to your homework when researching businesses in which to invest. - Warren Buffett As I appreciate the intellectual curiosity of Integrated BioSci Investing members, I'd like to share with you my analysis of the latest stock tip, GlycoMimetics ( GLY...
PRINCETON, N.J. , March 25, 2019 /PRNewswire/ -- Guerbet LLC USA , the U.S. affiliate of the global specialist in contrast media products and solutions for diagnostic and interventional imaging, today announced the end of temporary importation status for Lipiodol®...
SOUTH SAN FRANCISCO, Calif., March 04, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the Cowen and Company 39 th Annual Health Care Conference in Boston on Monday, March 11, 2019, at 4:50 p.m. Eastern Time. The prese...
Global Blood Therapeutics (NASDAQ: GBT ): Q4 GAAP EPS of -$0.93 misses by $0.04. More news on: Global Blood Therapeutics, Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Global Blood Therapeutics Inc. Company Name:
GBT Stock Symbol:
NASDAQ Market:
Global Blood Therapeutics Inc. Website:
Guerbet to Spotlight the Novel New Drug Elucirem™ (gadopiclenol) injection at the 2022 Radiological Society of North America Scientific Assembly and Annual Meeting PR Newswire Join us at Booth #1711 Opportunity to learn about the recently US FDA-approved nov...
The healthcare industry is growing at an unprecedented rate, and healthcare stocks are poised to benefit from this growth. This is large because healthcare companies are developing innovative new treatments and technologies that are transforming the way we care for our health. As a resu...
NEW YORK, NY / ACCESSWIRE / September 22, 2022 / New York, New York-Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: EVO Payments...